AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
stocks
Undervalued supermarket share sees sales improvement
Improving sales trends but recovery remains gradual.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.90 | 3.70 | 0.04% |
| CAC 40 | 8,117.78 | 61.99 | -0.76% |
| DAX 40 | 25,440.81 | 127.75 | -0.50% |
| Dow JONES (US) | 52,463.77 | 109.52 | -0.21% |
| FTSE 100 | 10,697.57 | 47.13 | 0.44% |
| HKSE | 24,917.60 | 111.97 | 0.45% |
| NASDAQ | 26,255.04 | 78.00 | -0.30% |
| Nikkei 225 | 63,492.99 | 518.35 | -0.81% |
| NZX 50 Index | 13,560.69 | 19.64 | -0.14% |
| S&P 500 | 7,631.22 | 25.76 | -0.34% |
| S&P/ASX 200 | 8,749.90 | 8.70 | 0.10% |
| SSE Composite Index | 3,885.33 | 2.78 | -0.07% |